Supplementary Figures 1-6 from Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells

Supplementary Figures 1-6. Supplementary Figure 1: CD133 correlates patient outcome with GIC selfrenewal and proliferative capacities in human GBM; Supplementary Figure 2: Gene Set Enrichment Analysis (GSEA) results for embryonic stem cell gene sets in CD133high- and CD133low-signature REMBRANDT samples; Supplementary Figure 3: CD133+ GICs are resistant to most compounds selected from CD133 connectivity mapping; Supplementary Figure 4: Pyrvinium specifically targets CD133+ GICs; Supplementary Figure 5: Overexpression of CD133; Supplementary Figure 6: Gene Set Enrichment Analysis (GSEA) results of Pyrvinium or DMSO control treated GICs